<DOC>
	<DOC>NCT01820637</DOC>
	<brief_summary>To determine whether the Boston Scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating Superficial Femoral (SFA) and/or Proximal Popliteal Artery (PPA) lesions.</brief_summary>
	<brief_title>Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Subjects age 18 and older Subject (or Legal Guardian if applicable) has signed the consent form and is willing and able to provide consent before any studyspecific tests or procedures are performed and agrees to attend all required followup visits Chronic, symptomatic lower limb ischemia defined as Rutherford categories 2, 3 or 4 Stenotic, restenotic (from angioplasty only, previous treatment with drug coated balloon is not allowed) or occlusive lesion(s) located in the native superficial femoral artery or proximal popliteal artery: 1. Degree of stenosis ≥70% by visual angiographic assessment 2. Vessel diameter ≥ 4 and ≤ 6mm 3. Total lesion length (or series of lesions) ≥30 mm and ≤110 mm (Note: tandem lesions may be treated, provided that the tandem lesion segment can be covered with only one stent) 4. Target lesion located at least three centimeters above the inferior edge of the femur Patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (&lt;50% stenosis) to the ankle or foot</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>SFA</keyword>
	<keyword>PPA</keyword>
	<keyword>lower extremities</keyword>
	<keyword>stenting</keyword>
	<keyword>paclitaxel</keyword>
</DOC>